SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

INCB123667

INCY·INCYTE CORP
MIXED
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
Likely 2029 or later, based on the estimated primary completion date of May 2029 for the MAESTRA 2 pivotal trial, assuming positive results and a subsequent regulatory filing.
Why 4/10
No hard binary catalyst (PDUFA or pivotal topline readout) is scheduled within the next 12 months; the MAESTRA 2 Phase 3 trial started Dec 2025 with estimated primary completion in May 2029. INCB123667 is a mid-stage pipeline asset at a diversified commercial-stage biotech where it represents a meaningful but not dominant portion of company value, scoring a default 4 per the rubric.
Actionable Insight MIXED

No hard binary catalyst (pivotal readout or FDA decision) is expected for INCB123667 within the next 12 months. The MAESTRA 2 Phase 3 trial started December 2025 with estimated completion in 2029. Investors should watch for interim data updates at medical conferences like ASCO 2027 (June) or ESMO 2027 (October), and for enrollment progress updates in Incyte quarterly earnings calls. Near-term value drivers for INCY stock are more likely to come from approved products (Jakafi, Opzelura) and nearer-term pipeline readouts for other assets like povorcitinib and INCA033989.

Price Chart

Loading chart...

Executive Summary

INCB123667 is Incyte's oral, selective CDK2 inhibitor targeting cyclin E1-overexpressing ovarian cancers, currently in Phase 3 development with two ongoing registration-directed trials (MAESTRA 2 in platinum-resistant disease and MAESTRA 3 in first-line maintenance). Early Phase 1 data showed a 33% objective response rate as monotherapy at the optimal dose, and ESMO 2026 data showed a 48% response rate in combination with bevacizumab. INCB123667 is the first CDK2 inhibitor to enter Phase 3, but pivotal readouts are likely years away (estimated completion 2029 for MAESTRA 2). The drug is one of several pipeline assets at Incyte, a diversified biotech with $5.2B+ in annual sales led by Jakafi and Opzelura, so this single asset represents a modest portion of total company value.

How It Works

INCB123667 is an oral pill that blocks CDK2, a protein that helps cancer cells divide and grow. Many ovarian cancers overproduce a partner protein called cyclin E1, making them especially dependent on CDK2. By inhibiting CDK2, the drug stops these cancer cells from multiplying and triggers their death. The drug is designed to be highly selective for CDK2 to avoid side effects on related cellular proteins.

Trial Status

Two Phase 3 trials are recruiting: MAESTRA 2 (NCT07214779), a randomized open-label study vs investigator's choice chemotherapy in ~466 patients with platinum-resistant ovarian cancer with cyclin E1 overexpression, started December 2025. MAESTRA 3 (NCT07797283), a double-blind randomized study of INCB123667 + bevacizumab vs bevacizumab alone as first-line maintenance in ~590 patients, registered September 2026. A Phase 1 monotherapy study (NCT05238922) has completed enrollment with data presented at ASCO 2025 and ESMO 2025/2026.

The Two-Sided Case

▲ Bull Case5
Phase 1 monotherapy data showed a 33% objective response rate at the recommended 100 mg QD dose in heavily pretreated platinum-resistant ovarian cancer, with over 70% of patients experiencing tumor shrinkage, which compares favorably to the 10-15% typical response rate of chemotherapy in this setting (source: Targeted Oncology/ASCO 2025)
ESMO 2026 Phase 1 combination data with bevacizumab showed a 48% objective response rate (11 of 23 patients), including in patients who had already failed PARP inhibitors and prior bevacizumab (source: OncoDaily/ESMO 2026)
INCB123667 is the first CDK2-selective inhibitor to advance to Phase 3, giving Incyte a potential first-mover advantage in the CDK2 inhibitor class for cyclin E1-overexpressing ovarian cancer (source: PharmCube)
Three distinct Phase 3 programs (MAESTRA 2 for resistant disease, MAESTRA 3 for first-line maintenance, plus Phase 1/2 in HR+ breast cancer) expand the potential addressable market beyond platinum-resistant ovarian cancer alone
Incyte has a strong balance sheet ($3.9B in cash) and commercial infrastructure to fund development and potential commercialization without needing partnership or financing (source: Incyte Q3 2026 8-K filing)
▼ Bear Case5
Phase 3 data are years away (MAESTRA 2 estimated completion May 2029), with no near-term binary catalyst to drive share price, making this a low-impact story for the stock in the next 12 months (source: ClinicalTrials.gov NCT07214779)
Competition is intensifying: Pfizer's atirmociclib (CDK2-selective), Incyclix Bio's INX-315, Relay Therapeutics' RGT-419B (CDK2/4/6), and AstraZeneca's AZD8421 are all in clinical development, any of which could beat INCB123667 to market or show superior data (source: Eureka/CDK2 Competitive Landscape 2026)
Early Phase 1 data are based on small patient numbers (30 patients at the optimal dose), and response rates often drop in larger randomized Phase 3 trials
Ovarian cancer with cyclin E1 overexpression is a biomarker-defined subset of an already niche indication, potentially limiting peak sales even with successful development
Incyte's stock is heavily dependent on Jakafi revenue (which generates ~63% of product sales), and the company faces an eventual patent cliff, making pipeline assets like INCB123667 important but distant value drivers that carry clinical and commercial risk

Upcoming Catalysts

  • Potential interim data updates at medical conferences (ASCO June 2027, ESMO October 2027)
  • Enrollment updates for MAESTRA 2 and MAESTRA 3 in quarterly earnings calls
  • Phase 1 data from combination studies (bevacizumab, endocrine therapy, CDK4/6 inhibitors)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

INCYTE CORP 8-K INCY ·Originating report

Sources · 12

Hover a chip for the title
1 clinicaltrials.gov2 clinicaltrials.gov3 ascopubs.org4 ascopubs.org5 oncodaily.com6 targetedonc.com7 global.pharmcube.com8 eureka.patsnap.com9 morningglorysciences.com10 sec.gov11 seekingalpha.com12 cancer.gov